Immunoreactivity for cyclin D1 is a reliable marker of gene aberration in plasma cell myeloma but does not specify patients prognosis.
Pruneri
Giancarlo
G
Alietti
Alessandra
A
Agnelli
Luca
L
Morabito
Fortunato
F
Laszlo
Daniele
D
Calabrese
Liliana
L
Fabris
Sonia
S
Bertolini
Francesco
F
Agazzi
Alberto
A
Bottiglieri
Luca
L
Raviele
Paola Rafaniello
PR
Baldini
Luca
L
Pileri
Stefano
S
Sabattini
Elena
E
Bosari
Silvano
S
Maisonneuve
Patrick
P
Lambertenghi-Deliliers
Giorgio
G
Bertoni
Francesco
F
Martinelli
Giovanni
G
Viale
Giuseppe
G
Neri
Antonino
A
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000032:analysis* / Q000235:genetics / Q000276:immunology; D056741:Cyclin D; D016213:Cyclins / Q000032:analysis* / Q000235:genetics / Q000276:immunology; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000175:diagnosis* / Q000235:genetics* / Q000401:mortality; D011379:Prognosis; D016019:Survival Analysis; D014178:Translocation, Genetic
D014408:Biomarkers, Tumor; D056741:Cyclin D; D016213:Cyclins